Compare IDEXX Laboratories, Inc. (IDXX) vs JD.Com Inc (JD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs JD.Com Inc — how do they compare? IDEXX Laboratories, Inc. trades at $572.59 (market cap $46.22B), while JD.Com Inc trades at $31.4 (market cap $44.04B). The key difference: IDEXX Laboratories, Inc. and JD.Com Inc are close in size by market cap, and JD.Com Inc pays a 3.13% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | JD | |
|---|---|---|
Market Cap | $46.22B | $44.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $36.17 |
52-Week Low | $526.44 | $25.19 |
Enterprise Value | $47.12B | $30.10B |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
JD stock trades at $31.29, down 6.51% over 24 hours, amid broader pressure on Chinese equities. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue grew to $1.31 trillion in 2025. Technical indicators show a bullish overall signal, with RSI at 28.66 suggesting potential oversold conditions. Analyst consensus remains strongly bullish with a $38.00 price target.
The outlook is positive given earnings beats and low valuation multiples like P/S of 0.24, but risks include regulatory scrutiny from the EU over the Ceconomy deal and margin pressures from expansion costs. Upside potential exists if Q2 results on August 13, 2026, exceed expectations, though macroeconomic headwinds for Chinese stocks pose a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →
